MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.

BACKGROUND: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.
METHODS: This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.
RESULTS: Doses of IFN 9 MIU/MG98 125 mg/m(2) for a continuous schedule and IFN 9 MIU/MG98 200 mg/m(2) for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD.
CONCLUSION: MG98 combined with IFN was safe and resulted in clinical activity.

RCT Entities:   Population Interventions Outcomes